“The North Coast, particularly Ras al-Hikma, has seen substantial investments, including a $35 billion development agreement ...

Major regional industry names are among early sponsors and exhibitor signings, including Sudair Pharma, Tabuk Pharmaceuticals ...

It is also approved for maintenance treatment of chronic obstructive pulmonary disease (COPD) and the reduction of COPD exacerbations in patients with a history ... and Hikma have tried ...

Horrya Press: In the face of severe financial strain and mounting debt, Egypt’s ambitious New Administrative Capital stands ...

IBD is a chronic inflammation of the intestine characterised by severe stomach pain and diarrhoea affecting nearly 5 million people worldwide Riyadh – Hikma Pharmaceuticals KSA, announced the ...

Hikma Pharmaceuticals PLC HIK shares inched up 0.88% to £19.53 Monday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.06% to ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics ...

Elevate your confidence by analyzing investor sentiment and stock portfolio shifts, then make your own decisions.

As of 09:03 BST. Market open. Loading Chart for HIK.L ...